AKBA Stock Recent News

Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - President and Chief Executive Officer Nicholas Grund - Senior Vice President, Chief Commercial Officer Erik Ostrowski - Senior Vice President, Chief Financial Officer and Chief Business Officer Conference Call Participants Julian Harrison - BTIG Ed Arce - H.C. Wainwright Operator Thank you for standing by.

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.06 per share a year ago.

Vafseo ® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 million Akebia to host conference call at 8:00 a.m. ET on August 8 CAMBRIDGE, Mass.

Akebia to Host Conference Call on August 8, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.

CAMBRIDGE, Mass. , Aug. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 47,000 shares of Akebia's common stock on July 31, 2024.

CAMBRIDGE, Mass. , July 29, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024, and Canaccord Genuity (CG) 44th Annual Growth Conference, August 13-14, 2024 in Boston.

Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economics Announced Vafseo WAC pricing of $1,278 for a 30-day supply Submitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025 Akebia to host investor conference call at 8:00 a.m. ET on July 11, 2024 CAMBRIDGE, Mass.

CAMBRIDGE, Mass. , July 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 517,000 shares of Akebia's common stock on June 28, 2024, including an option to purchase 500,000 shares to Erik Ostrowski, Akebia's newly hired Chief Financial Officer and Chief Business Officer.